Katia Schlienger, MD, PhD, was appointed Executive Vice President, Clinical Research and Development in July 2022. In her role, Katia is responsible for all clinical development programs at HOOKIPA, inclusive of Oncology and Infectious Diseases. Katia joined HOOKIPA in January 2021 as Senior Vice President, Head of Immuno-Oncology Clinical Research and Development. She has had primary responsibility for the execution of the HB-200 therapeutic program for HPV16+ cancers, and its progression from Phase 1 to Phase 2. She was also instrumental in developing new clinical assets for prostate cancer and KRAS mutated tumors.
Prior to HOOKIPA, Schlienger worked at Merck & Co., for 14 years, serving in roles of increasing responsibility across early and late-stage clinical development in oncology and vaccines. Her expertise extends from clinical research to regulatory and strategic development of novel therapies and vaccines. Earlier in her career, Katia was a Research Assistant Professor at University of Pennsylvania, where she worked in Carl June’s laboratory on immunotherapy of ovarian cancer and non-Hodgkin lymphoma.
Katia has authored or co-authored more than 30 scientific papers in the areas of virology, immunology and oncology.
Katia is an MD trained at the School of Medicine Lariboisière Saint-Louis, Paris, France. She did her residency in clinical pathology at Hôpital Charles Nicolle in Rouen, France and obtained her PhD in Microbiology/Virology from Paris Diderot University, where she worked on developing a prototype HIV vaccine in Pierre Tiollais’ laboratory at the Pasteur Institute.